España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
TC BioPharm (Holdings)
TCBPW
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.0199
0.00090
4.74%
Pre-Market: Jan 14, 5:29 AM EDT
Get Report
Comment
TC BioPharm (Holdings) (TCBPW) Forecast
News
Earnings
TC BioPharm (Holdings) (TCBPW) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for TC BioPharm (Holdings) (NASDAQ:TCBPW) Stock
TC BioPharm (Holdings) Stock (NASDAQ: TCBPW)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, August 05, 2024
Trading Halt: Halt status updated at 9:00:00 ...
Benzinga Newsdesk
Tuesday, February 21, 2023
TC BioPharm Shares Halted On Circuit Breaker; Stock Trading Lower During The Company's Shareholder Update Conference Call
Happy Mohamed
TC BioPharm Announces Publication Of Paper In AML Research Highlighting The Company's Development Of Allogeneic Gamma-Delta T Cell Therapies
Happy Mohamed
Tuesday, February 14, 2023
TC BioPharm Announces New Chair Of The Board, Arlene Morris
Happy Mohamed
Thursday, January 19, 2023
TC BioPharm Receives Notice Of Non-compliance...
Benzinga Newsdesk
Tuesday, January 17, 2023
TC BioPharm Announces Strategic Collaboration...
Benzinga Newsdesk
Monday, November 28, 2022
TC BioPharm Announces $7.35M Private Placemen...
Benzinga Newsdesk
Tuesday, November 22, 2022
TC BioPharm Doses First 3 Patients in Phase 2b Clinical Trial of Lead Compound, OmnImmune®, To Treat Acute Myeloid Leukemia
Kenneth Adams
-
Sponsored
TC BioPharm Begins Dosing Phase 2B Clinical S...
Benzinga Newsdesk
Tuesday, September 13, 2022
TC BioPharm Receives MHRA Approval For 18-Mon...
Benzinga Newsdesk
Wednesday, May 18, 2022
TC BioPharm Announces Formation Of Scientific...
Benzinga Newsdesk
Wednesday, April 06, 2022
TC BioPharm Receives CryoTC Trademark For Proprietary Cell Freezing Process
Bill Haddad
Wednesday, March 23, 2022
TC Biopharm Reports Received Medicines and He...
Benzinga Newsdesk
Thursday, March 17, 2022
TC Biopharm Reports FDA Orphan Drug Status Gr...
Benzinga Newsdesk
Tuesday, March 08, 2022
TC Biopharm Reports Phase 1b/2a Data In Late-...
Benzinga Newsdesk
Friday, February 11, 2022
TC Biopharm Announces Priced ~4.11M Share/~8.23M Warrant IPO @$4.25
Charles Gross
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
